narcolepsy in adults - Viral Trends
Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ... Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...
Understanding the Context
WSIL-TV: Life with narcolepsy: ‘It’s not a joke, it’s a very serious illness’ Narcolepsy is estimated to affect one in 2,000 people in the United States and some 3 million worldwide, according to the Narcolepsy Network, a non-profit patient advocacy group. However, that ... Life with narcolepsy: ‘It’s not a joke, it’s a very serious illness’ Healio: FDA OKs supplemental NDA for Lumryz in patients aged 7 years and older with narcolepsy FDA OKs supplemental NDA for Lumryz in patients aged 7 years and older with narcolepsy Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...